Neuroprotective agents are drugs, outside of those used to re-establish perfusion to an infarcted region of the brain, that aim to salvage or protect vulnerable brain tissue during an insult. These drugs are diverse and can act by inhibiting steps in the apoptotic pathway, scavenging damaging species like free radical oxidative species, reducing inflammatory responses, and changing the extracellular environment, among other mechanisms. In this chapter, we will discuss neuroprotective drugs used in recent human clinical trials for acute ischemic stroke, their mechanisms of action, and potential avenues for future research in the discipline of neuroprotection.
|Title of host publication
|Drug Discovery for Leishmaniasis
|Svetlana A. Dambinova, Thomas A. Gennarelli, Philip V. Peplow, Thomas A. Gennarelli, Bridget Martinez
|Number of pages
|Published - 2018
|RSC Drug Discovery Series
Bibliographical noteFunding Information:
Drug Discovery Series No. 62 Acute Brain Impairment: Scientific Discoveries and Translational Research Edited by Philip V. Peplow, Svetlana A. Dambinova, Thomas A. Gennarelli and Bridget Martinez © The Royal Society of Chemistry 2018 Published by the Royal Society of Chemistry, www.rsc.org
© The Royal Society of Chemistry 2018.
ASJC Scopus subject areas
- Drug Discovery